PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo).  PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).

News

PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024

PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024

PDC*lung01, in combination with pembrolizumab, demonstrates the potential to provide meaningful clinical benefit compared to

PDC*line Pharma has been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI)

We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI), held in Strasbourg from October 9 to 11, 2024!
The presentation